Cat No.
CEI-0551
Description
Cell-permeable. A slow-release prodrug version of Ro 61-8048, an inhibitor of KMO (kynurenine 3-monooxygenase), the enzyme that controls the kynurenine pathway, long believed to be implicated in neurodegeneration. JM6 reverses and prevents symptoms of neurodegenerative diseases like Alzheimer’s and Huntington’s in animal models. JM6 does not penetrate into the brain, but works by inhibiting KMO in the blood.
Product_Overview
A high-affinity inhibitor of KMO (kynurenine 3-monoxygenase or kynurenine 3-hydroxylase)
Targets
KMO
Chemical Name
2-(3,4-Dimethoxybenzenesulfonylamino)-4-(3-Nitrophenyl)-5-(Piperidin-1-yl)Methylthiazole
M.Wt
696.7
Purity
>95% by HPLC
Appearance
Liquid
Formulation
DMSO ( 4 mM)
Storage
-20 centigrade
Shipping Conditions
Gel pack
Handling
Protect from light and moisture
Usage
For Research Use Only! Not For Use in Humans.
